OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Jul 2019 to Jul 2024
OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral
fluid diagnostics, today announced its support of National Black
HIV/AIDS Awareness Day (NBHAAD), through the distribution of
complimentary OraQuick ADVANCE® Rapid HIV-1/2
Antibody Test kits and educational materials to more than 25 HIV testing
sites across the country, including state and city public health
departments and community-based organizations. The tests and materials
will be utilized in observance of NBHAAD on February 7, 2008, to
encourage African Americans to learn their HIV status.
According to the Centers for Disease Control and Prevention (CDC), even
though blacks account for approximately 13% of the U.S. population, they
account for about half (49%) of the people who get HIV and AIDS.
HIV/AIDS continues to be a leading cause of death among African
Americans in the United States according to the CDC.
"OraSure is committed to combating HIV/AIDS in the African American
community and we are proud to support National Black HIV AIDS Awareness
Day," said Douglas A. Michels, OraSure's President and Chief Executive
Officer. "Knowing one’s HIV status is a
critical first step to getting individuals into care and stemming the
spread of the disease and we recognize that our test plays an important
role in empowering individuals to know their status.”
Committed to working collaboratively with local and national agencies to
fight against HIV/AIDS, OraSure is actively supporting over 25 testing
and education programs, including programs in New York, Georgia, Puerto
Rico, Washington D.C., and the U.S. Virgin Islands among others, that
urge people to learn their HIV status.
The OraQuick ADVANCE® Rapid HIV-1/2 Antibody
Test, manufactured and sold by OraSure Technologies, is the first and
only U.S. Food and Drug Administration ("FDA") approved and CLIA
(Clinical Laboratory Improvements Amendments Act of 1988) waived rapid
point-of-care test that can detect antibodies to both HIV-1 and HIV-2 in
20 minutes, using oral fluid, finger-stick or venipuncture whole blood
and plasma specimens.
The mission of NBHAAD is to build the capacity and increase awareness,
participation and support for HIV prevention, care and treatment among
African Americans. The observance is directed, planned and organized by
the Strategic Leadership Council, which partners with the CDC to
mobilize communities and address specific issues regarding local
epidemics and best practices that are science-based and will influence
the course of HIV in Black communities across the country.
About OraSure Technologies
OraSure Technologies develops, manufactures and markets oral fluid
specimen collection devices using proprietary oral fluid technologies,
diagnostic products including immunoassays and other in vitro
diagnostic tests, and other medical devices. These products are sold in
the United States as well as internationally to various clinical
laboratories, hospitals, clinics, community-based organizations and
other public health organizations, distributors, government agencies,
physicians' offices, and commercial and industrial entities.
In addition, OraSure sells products for the cryosurgical removal of
common and plantar warts in the over-the-counter or retail market in
Mexico, Canada, certain European countries, Australia and New Zealand,
and a product for the cryosurgical removal of common and plantar warts
and several other benign skin lesions to the professional or physician
office market in the United States and many foreign countries. For more
information on the Company, please go to http://www.orasure.com.